Takeda Pharmaceutical Co Ltd
TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
$21.77+0.36 (+1.68%)
Close on Nov 20, 2026Market cap $75.03BP/E –Yield –
Takeda Pharmaceutical Net Debt (IFRS Book Value Basis): -4,157.10 JPY billion in Q2 FY27, up 4.9% from a year earlier.
Latest, Q2 FY27
-4,157.10
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+4.9%
-3,963.80 in Q2 FY26
History
11 quarters
Since Q4 FY24
Sources
10
Documents cited below
Where the Q2 FY27 figure comes from
“|| Net Debt *1 | (4,157.1) | Acquisition of intangible assets | (39.9) | (60.5)”
Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗
Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Debt (IFRS Book Value Basis) | Year on year | Source |
|---|---|---|---|---|
| Q2 FY27CQ3 2026 | Sep 30, 2026 | -4,157.10 | +4.9% | SEC EDGAR Filing (exhibit991_102926.htm) ↗ |
| Q1 FY27CQ2 2026 | Jun 30, 2026 | -4,479.00 | +7.8% | SEC EDGAR Filing (exhibit991_073026.htm) ↗ |
| Q4 FY26CQ1 2026 | Mar 31, 2026 | -4,286.80 | +3.8% | SEC EDGAR Filing (exhibit991_051326.htm) ↗ |
| Q3 FY26CQ4 2025 | Dec 31, 2025 | -4,198.40 | -3.4% | SEC EDGAR Filing (exhibit991_012926.htm) ↗ |
| Q2 FY26CQ3 2025 | Sep 30, 2025 | -3,963.80 | -5.4% | SEC EDGAR Filing (exhibit991_103025.htm) ↗ |
| Q1 FY26CQ2 2025 | Jun 30, 2025 | -4,155.90 | -11.1% | SEC EDGAR Filing (exhibit991_073025.htm) ↗ |
| Q4 FY25CQ1 2025 | Mar 31, 2025 | -4,130.20 | -5.8% | SEC EDGAR Filing (exhibit991_050825.htm) ↗ |
| Q3 FY25CQ4 2024 | Dec 31, 2024 | -4,346.00 | – | SEC EDGAR Filing (exhibit991_013025.htm) ↗ |
| Q2 FY25CQ3 2024 | Sep 30, 2024 | -4,192.20 | – | SEC EDGAR Filing (exhibit991_103124.htm) ↗ |
| Q1 FY25CQ2 2024 | Jun 30, 2024 | -4,676.70 | – | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
| Q4 FY24CQ1 2024 | Mar 31, 2024 | -4,386.00 | – | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
Cite this data
StockData. (2026). Takeda Pharmaceutical Net Debt (IFRS Book Value Basis), quarterly Q4 FY24–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-net-debt
See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?